Naslov (srp)

Estroprogestageni u terapiji sekundarne hipertenzije u menopauzi : doktorska disertacija

Autor

Đogo, Aleksandar

Doprinosi

Hajduković, Zoran, 1958-
Popović, Srđan, 1958-
Srebro, Dragana, 1986-
Vujović, Svetlana, 1962-
Dožić, Ivan, 1967-

Opis (srp)

Menopauza predstavlja period u životu žene, koji počinje godinu dana nakon posljednje menstruacije i traje do kraja života. Karakterisana je opadajućom koncentracijom polnih steroida. Hipoestrogenemija dovodi do porasta krvnog pritiska putem porasta simpatičke aktivnosti i smanjenog elasticiteta arterija. Hipoprogesteronemija uzrokuje retenciju natrijuma. Značajan je poremećaj lipidnog statusa.Cilj. Ispitivanje uticaja estroprogestagena na hipertenziju i metabolizam lipida kod žena u menopauzi. Metode. Istraživanje je sprovedeno po tipu retrospektivne kliničke interventne kontrolisane studije paralelnih grupa. Obuhvatilo je 64 žene u menopauzi, podjeljene u tri grupe: grupa 1 (N=22), na oralnim estroprogestagenima, grupa 2 (N=17), na transdermalnim i grupa 3 (N=25) na intramuskularnim preparatima. Za procjenu hormonskog statusa određivani su folikulostimulišući hormon (IU/L), luteinizujući hormon (IU/L), estradiol (pmol/L), progesteron (nmol/L), testosteron (nmol/L), vezujući globulin za seksualne hormone (nmol/L), dehidroepiandrosteron-sulfat (μmol/L), prolaktin (mIU/L) i tireostimulišući hormon (mIU/L). Lipidni status je definisan ukupnim holesterolom (mmol/L), HDL (mmol/L), LDL (mmo/L), trigliceridima (mmol/L), lipoproteino (a) (g/L), apolipoproteinom A (g/L) i apolipoproteinom B (g/L). Hormonogram i lipidogram su određivani prije i tokom 6 do 12 mjeseci primjene terapije. Krvni pritisak je izmjerena Meditech ABP aparatom, uz interval mjerenja na 15minuta, a potom je urađen 24h holter monitoring krvnog pritiska, prije i tokom 6 do 12 mjeseci tretmana. Rezultati. Nađen je statistički značajan pad vrijednosti sistolnog i dijastolnog krvnog pritiska i srčane frekfrence primjenom terapije, kao i povoljne promjene u lipidogramu. Zaključak. Estroprogesteronska supstitucija ima povoljan kardiovaskularni efekat.

Opis (srp)

medicina - endokrinologija / Medicine- Endocrinology Datum odbrane: 08.09.2022.

Opis (eng)

Menopause is period in woman's life, which begins one year after the last menstrual period and lasts until the end of life. It is characterized by declining concentration of sex steroids. Hypoestrogenemia leads to increase in blood pressure through increase in sympathetic activity and decreased elasticity of arteries. Hypoprogesteronemia causes sodium retention. Lipid status disorder is significant. Aim. To investigate influence of estroprogestagen on hypertension and lipid metabolism in menopausal women. Methods. The research was conducted according to the type of Retrospective Clinical Intervention Controlled Study of Parallel Groups. It included 64 menopausal women, divided into three groups: group1 (N=22), on oral estroprogestagens, group2 (N=17), on transdermal and group3 (N=25) on intramuscular preparations. To assess hormonal status follicle-stimulating (IU/L), luteinizing hormone (IU/L), estradiol (pmol/L), progesterone (nmol/L), testosterone (nmol/L), sex hormone binding globulin (nmol/L), dehydroepiandrosterone sulfate (μmol/L), prolactin (mIU/L) and thyroid-stimulating hormone (mIU/L). Lipid status is defined by total cholesterol (mmol /L),HDL (mmol/L), LDL (mmol/L), triglycerides (mmol/L), lipoprotein (a) (g/L), apolipoproteinA (g/L) and apolipoprotein B (g/L). Hormonogram and lipidogram were determined before and during 6 to 12 months therapy. Blood preasure was measured with Meditech ABP device, with measurement interval of 15 minutes, and then 24 h holter monitoring of tension was performed, before and during 6 to 12 months of treatment. Results. Statistically significant decrease in systolic and diastolic blood pressure and heart rate with the application of therapy, as favorable changes in the lipidogram. Conclusion. Estroprogesterone substitution has favorable cardiovascular effect.

Jezik

srpski

Datum

2021

Licenca

© All rights reserved

Predmet

OSNO - Opšta sistematizacija naučnih oblasti, Endokrini sistem

estroprogestagens, hormone therapy in menopause, secondary arterial hypertension, lipid status

OSNO - Opšta sistematizacija naučnih oblasti, Endokrini sistem

estroprogestageni, hormonska terapija u menopauzi, sekundarna arterijska hipertenzija, lipidni status

616.4:616.12‑008.331.1-055.2(043.3)